These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22042222)

  • 1. Activated platelets contribute to oxidized low-density lipoproteins and dysfunctional high-density lipoproteins through a phospholipase A2-dependent mechanism.
    Blache D; Gautier T; Tietge UJ; Lagrost L
    FASEB J; 2012 Feb; 26(2):927-37. PubMed ID: 22042222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
    Luchtefeld M; Bandlow N; Tietge UJ; Grote K; Pfeilschifter J; Kaszkin M; Beck S; Drexler H; Schieffer B
    Atherosclerosis; 2007 Sep; 194(1):62-70. PubMed ID: 17069818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis.
    Staprans I; Pan XM; Rapp JH; Feingold KR
    Mol Nutr Food Res; 2005 Nov; 49(11):1075-82. PubMed ID: 16270280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis.
    Mertens A; Verhamme P; Bielicki JK; Phillips MC; Quarck R; Verreth W; Stengel D; Ninio E; Navab M; Mackness B; Mackness M; Holvoet P
    Circulation; 2003 Apr; 107(12):1640-6. PubMed ID: 12668499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma very-low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein oxidative modification induces procoagulant profiles in endogenous hypertriglyceridemia.
    Bai H; Liu BW; Deng ZY; Shen T; Fang DZ; Zhao YH; Liu Y
    Free Radic Biol Med; 2006 May; 40(10):1796-803. PubMed ID: 16678017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal injection of platelet secretory products into mice increases macrophage uptake of oxidized low density lipoprotein.
    Hussein O; Brook GJ; Aviram M
    Isr J Med Sci; 1993 Aug; 29(8):453-9. PubMed ID: 8407271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of plasma very low density lipoprotein, low density lipoprotein and high density lipoprotein on platelet aggregation in endogenous hypertriglyceridemia].
    Deng Z; Liu B; Zhou J; Zhang Z; Liu Y; Bai H
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 34(4):704-7. PubMed ID: 14619587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of oxidized low-density lipoprotein on circulating platelets is increased in patients with acute coronary syndromes and induces platelet adhesion to vascular wall in vivo--brief report.
    Stellos K; Sauter R; Fahrleitner M; Grimm J; Stakos D; Emschermann F; Panagiota V; Gnerlich S; Perk A; Schönberger T; Bigalke B; Langer HF; Gawaz M
    Arterioscler Thromb Vasc Biol; 2012 Aug; 32(8):2017-20. PubMed ID: 22701021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis.
    Siegel-Axel D; Daub K; Seizer P; Lindemann S; Gawaz M
    Cardiovasc Res; 2008 Apr; 78(1):8-17. PubMed ID: 18218686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.
    Leitinger N; Watson AD; Hama SY; Ivandic B; Qiao JH; Huber J; Faull KF; Grass DS; Navab M; Fogelman AM; de Beer FC; Lusis AJ; Berliner JA
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1291-8. PubMed ID: 10323782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
    Berti JA; Amaral ME; Boschero AC; Nunes VS; Harada LM; Castilho LN; Oliveira HC
    Metabolism; 2001 May; 50(5):530-6. PubMed ID: 11319713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.
    Fraser H; Hislop C; Christie RM; Rick HL; Reidy CA; Chouinard ML; Eacho PI; Gould KE; Trias J
    J Cardiovasc Pharmacol; 2009 Jan; 53(1):60-5. PubMed ID: 19129734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of oxidized lipoproteins in the pathogenesis of atherosclerosis.
    Kita T; Yokode M; Ishii K; Kume N; Nagano Y; Arai H; Otani H; Ueda Y; Hara S
    Clin Exp Pharmacol Physiol Suppl; 1992; 20():37-42. PubMed ID: 1446408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress.
    Tietge UJ; Pratico D; Ding T; Funk CD; Hildebrand RB; Van Berkel T; Van Eck M
    J Lipid Res; 2005 Aug; 46(8):1604-14. PubMed ID: 15897607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of in vivo oxidized high-density lipoproteins on platelet aggregation: evidence from patients with abetalipoproteinemia.
    Calzada C; Véricel E; Colas R; Guillot N; El Khoury G; Drai J; Sassolas A; Peretti N; Ponsin G; Lagarde M; Moulin P
    FASEB J; 2013 Jul; 27(7):2855-61. PubMed ID: 23507868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.
    Hanasaki K; Yamada K; Yamamoto S; Ishimoto Y; Saiga A; Ono T; Ikeda M; Notoya M; Kamitani S; Arita H
    J Biol Chem; 2002 Aug; 277(32):29116-24. PubMed ID: 12021277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.
    Noto H; Hara M; Karasawa K; Iso-O N; Satoh H; Togo M; Hashimoto Y; Yamada Y; Kosaka T; Kawamura M; Kimura S; Tsukamoto K
    Arterioscler Thromb Vasc Biol; 2003 May; 23(5):829-35. PubMed ID: 12649088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hypochlorite-modified low-density and high-density lipoproteins on intracellular Ca2+ and plasma membrane Ca(2+)-ATPase activity of human platelets.
    Zabe M; Feltzer RE; Malle E; Sattler W; Dean WL
    Cell Calcium; 1999 Dec; 26(6):281-7. PubMed ID: 10668566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.